Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lilly launches pivotal trial for targeted oral cancer agent
Enzastaurin is an oral serine-threonine kinase inhibitor that is designed to suppress tumor growth through a distinct mechanism of action. In the phase III clinical trial, enzastaurin will
Enzastaurin is an oral serine-threonine kinase inhibitor that is designed to suppress tumor growth through a distinct mechanism of action. In the phase III clinical trial, enzastaurin will
The boards of both companies have approved the transaction, which is expected to close in two months. Financial terms of the transaction were not disclosed. Fumapharm, founded in
This agreement expands the existing licensing and distribution arrangement between Labopharm and GSK for 20 Latin American and Caribbean countries entered into in September 2005. “Similar to that
Omnitrope, which is produced by Novartis' generics division Sandoz, is a copycat version of Pfizer's biotechnology product Genotropin. The approval marks the first time a biogeneric drug has
Pfizer revealed in February that it was considering the sale of its consumer healthcare operations. Although the unit generated sales of almost $4 billion last year, Pfizer stated
The decision came after the FDA examined data from a clinical trial into gender-specific lung cancer. The US-based biopharmaceutical company announced that the FDA had agreed on a
Under the terms of the agreement CFFT, the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, will award CombinatoRx up to $13.8 million in research
Vical announced that in the clinical trial, a West Nile virus (WNV) vaccine candidate administered using Vical’s proprietary DNA delivery technology was safe and well tolerated. It produced
HoFH is a rare genetic disorder that results in extremely high cholesterol. Patients with this disease display signs of high cholesterol early in life and may experience heart
This pivotal US study will enroll 360 patients with moderate-to-severe postoperative pain following abdominal surgery. A second study in a different postoperative pain model (orthopedic surgery) is planned